Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) CEO Anhco Nguyen sold 6,094 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $6.46, for a total transaction of $39,367.24. Following the completion of the transaction, the chief executive officer directly owned 126,681 shares of the company’s stock, valued at approximately $818,359.26. This trade represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Atara Biotherapeutics Stock Up 4.2%
ATRA traded up $0.27 during trading on Wednesday, reaching $6.77. 15,314 shares of the company were exchanged, compared to its average volume of 542,389. The company’s 50-day moving average is $8.80 and its two-hundred day moving average is $7.85. The company has a market cap of $68.99 million, a price-to-earnings ratio of -6.70 and a beta of 0.28. Atara Biotherapeutics, Inc. has a 12-month low of $3.92 and a 12-month high of $19.15.
Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report) last posted its earnings results on Tuesday, November 10th. The biotechnology company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The company had revenue of $1.22 million for the quarter, compared to analyst estimates of $0.80 million. Equities analysts forecast that Atara Biotherapeutics, Inc. will post -0.22 earnings per share for the current year.
Analyst Ratings Changes
ATRA has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Atara Biotherapeutics in a research report on Monday. TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Finally, Wall Street Zen raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Atara Biotherapeutics has a consensus rating of “Moderate Buy” and an average price target of $9.50.
Read Our Latest Stock Report on Atara Biotherapeutics
Institutional Trading of Atara Biotherapeutics
An institutional investor recently bought a new stake in Atara Biotherapeutics stock. Empowered Funds LLC acquired a new position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 13,760 shares of the biotechnology company’s stock, valued at approximately $117,000. Empowered Funds LLC owned 0.14% of Atara Biotherapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 70.90% of the company’s stock.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics is a biotechnology company focused on developing allogeneic T-cell immunotherapies for cancer and other serious diseases. Founded in 2012 and based in Thousand Oaks, California, the company’s approach uses immune cells from donors rather than cells collected from each individual patient. Its lead therapy, tabelecleucel, is an Epstein-Barr virus (EBV)-specific T-cell treatment for EBV-positive post-transplant lymphoproliferative disease, a rare complication that can occur after an organ or stem-cell transplant.
Recommended Stories
- Five stocks we like better than Atara Biotherapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
